Diabetic macular edema is the main cause of vision loss in patients with diabetic retinopathy. In this work, we aimed to assess the role of Optical Coherence Tomography (OCT) biomarkers in patients treated with ranibizumab.
Methods
A prospective study enrolling 46 eyes with DME under ranibizumab intravitreal therapy with 12 months of follow-up. The primary endpoint was to assess the association between OCT biomarkers at baseline and the type of treatment response.
Results
Good responders, compared with partial/non responders, had lower number of inner nuclear layer cysts (INLc) at baseline, (26.5% vs 73.5%, p = 0.035) and presented, at 12 months of follow-up, lower percentage of disorganization of retinal inner layers (12.0% vs 88.0%, p = 0.001), lower disruption of outer plexiform layer (8.7% vs 91.3%, p < 0.001) and lower outer nuclear layer cysts (17.4% vs 82.6%, p = 0.013). At the end of follow-up, it was observed a higher frequency of inner nuclear layer cysts in patients with higher glycated haemoglobin (p = 0.028).
Conclusion
This study showed the value and importance of OCT parameters, such as absence of INLc, as a prognostic therapeutic response. A normalization of the macular anatomy with ranibizumab is more likely to happen in early complete responders. The association between INLc and higher glycated haemoglobin levels showed the importance of systemic metabolic control in systemic diabetic manifestations. Clinicaltrials.gov NCT04387604.
StandlEKhuntiKHansenTB, et al.The global epidemics of diabetes in the 21st century: current situation and perspectives. Eur J Prev Cardiol2019; 26: 7–14. DOI: https://doi.org/10.1177/2047487319881021
2.
LeeRWongTYSabanayagamC. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond)2015; 2: 17. DOI: https://doi.org/10.1186/s40662-015-0026-2
3.
PanozzoGCicinelliMVAugustinAJ, et al.An optical coherence tomography-based grading of diabetic maculopathy proposed by an international expert panel: the European School for Advanced Studies in Ophthalmology classification. Eur J Ophthalmol2020; 30: 8–18. DOI: https://doi.org/10.1177/1120672119880394
4.
SimóRStittAWGardnerTW. Neurodegeneration in diabetic retinopathy: does it really matter?Diabetologia2018; 61: 1902–1912. DOI: https://doi.org/10.1007/s00125-018-4692-1
5.
SongWSinghRPRachitskayaAV. The effect of delay in care among patients requiring intravitreal injections. Ophthalmol Retina2021. DOI: https://doi.org/10.1016/j.oret.2020.12.020
6.
EhlkenCHelmsMBöhringerD, et al.Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol2018; 12: 13–20. DOI: https://doi.org/10.2147/opth.S151611
7.
WeissMSimDAHeroldT, et al.Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina2018; 38: 2293–2300. DOI: https://doi.org/10.1097/iae.0000000000001892
8.
GonzalezVHCampbellJHolekampNM, et al.Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol2016; 172: 72–79. DOI: https://doi.org/10.1016/j.ajo.2016.09.012
9.
BuschCFraser-BellSIglickiM, et al.Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results. Acta Diabetol2019; 56: 1341–1350. DOI: https://doi.org/10.1007/s00592-019-01416-4
10.
MaheshwaryASOsterSFYusonRM, et al.The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema. Am J Ophthalmol2010; 150: 63–67.e61. DOI: https://doi.org/10.1016/j.ajo.2010.01.039
11.
SunJKRadwanSHSolimanAZ, et al.Neural retinal disorganization as a robust marker of visual acuity in current and resolved diabetic macular edema. Diabetes2015; 64: 2560–2570. DOI: https://doi.org/10.2337/db14-0782
12.
ReznicekLCserhatiSSeidenstickerF, et al.Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment. Acta Ophthalmol2013; 91: e529–e536. DOI: https://doi.org/10.1111/aos.12153
13.
VujosevicSTorresinTBertonM, et al.Diabetic macular edema with and without subfoveal neuroretinal detachment: two different morphologic and functional entities. Am J Ophthalmol2017; 181: 149–155. DOI: https://doi.org/10.1016/j.ajo.2017.06.026
14.
BuschCOkadaMZurD, et al.Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity. Acta Ophthalmol2020; 98: e801–e806. DOI: https://doi.org/10.1111/aos.14390
15.
CavalleriMCicinelliMVParravanoM, et al.Prognostic role of optical coherence tomography after switch to dexamethasone in diabetic macular edema. Acta Diabetol2020; 57: 163–171. DOI: https://doi.org/10.1007/s00592-019-01389-4
16.
LeeJMoonBGChoAR, et al.Optical coherence tomography angiography of DME and its association with anti-VEGF treatment response. Ophthalmology2016; 123: 2368–2375. DOI: https://doi.org/10.1016/j.ophtha.2016.07.010
17.
PessoaBFerreiraALeiteJ, et al.Optical coherence tomography biomarkers - vitreous status influence in outcomes for diabetic macular edema therapy with 0.19 mg fluocinolone acetonide implant. Ophthalmic Res2021 . DOI: https://doi.org/10.1159/000515306
18.
PessoaBCoelhoJCoelhoC, et al.Enzymatic vitreolysis for the treatment of tractional diabetic macular edema. Ther Adv Ophthalmol2019; 11: 1–10. DOI: https://doi.org/10.1177/2515841419869511
19.
PessoaBLeiteJHeitorJ, et al.Vitrectomized versus non-vitrectomized eyes in diabetic macular edema response to ranibizumab-retinal layers thickness as prognostic biomarkers. Sci Rep2021; 11: 23055. DOI: https://doi.org/10.1038/s41598-021-02532-4
20.
GerendasBSBogunovicHSadeghipourA, et al.Computational image analysis for prognosis determination in DME. Vision Res2017; 139: 204–210. DOI: https://doi.org/10.1016/j.visres.2017.03.008
21.
CoscasGLupidiMCoscasF. Atlas of Oct-angiography in diabetic maculopathy. Paris: Société Française de Rétine, 2016.
22.
HasegawaNNozakiMTakaseN, et al.New insights into microaneurysms in the deep capillary Plexus detected by optical coherence tomography angiography in diabetic macular edema. Invest Ophthalmol Visual Sci2016; 57: 348–355. DOI: https://doi.org/10.1167/iovs.15-18782
NagaiNSuzukiMUchidaA, et al.The area and number of intraretinal cystoid spaces predict the visual outcome after ranibizumab monotherapy in diabetic macular edema. J Clin Med2020; 9. DOI: https://doi.org/10.3390/jcm9051391
25.
GerendasBSPragerSDeakG, et al.Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema. Br J Ophthalmol2018; 102: 195–203. DOI: https://doi.org/10.1136/bjophthalmol-2017-310483
26.
DeakGGBolzMRitterM, et al.A systematic correlation between morphology and functional alterations in diabetic macular edema. Invest Ophthalmol Visual Sci2010; 51: 6710–6714. DOI: https://doi.org/10.1167/iovs.09-5064
27.
YalcinGOzdekSBaran AksakalFN. Defining cystoid macular degeneration in diabetic macular edema: an OCT-based single-center study. Turk J Ophthalmol2019; 49: 315–322. DOI: https://doi.org/10.4274/tjo.galenos.2019.22687
28.
LaiCTHsiehYTLinCJ, et al.Age, initial central retinal thickness, and OCT biomarkers have an influence on the outcome of diabetic macular edema treated with ranibizumab- tri-center 12-month treat-and-extend study. Front Med (Lausanne)2021; 8: 668107. DOI: https://doi.org/10.3389/fmed.2021.668107
29.
PayneJFWykoffCCClarkWL, et al.Randomized trial of treat and extend ranibizumab with and without navigated Laser versus monthly dosing for diabetic macular edema: TREX-DME 2-year outcomes. Am J Ophthalmol2019; 202: 91–99. DOI: https://doi.org/10.1016/j.ajo.2019.02.005
30.
AbrahamJRWykoffCCArepalliS, et al.Aqueous cytokine expression and higher order OCT biomarkers: assessment of the anatomic-biologic bridge in the IMAGINE DME study. Am J Ophthalmol2021; 222: 328–339. DOI: https://doi.org/10.1016/j.ajo.2020.08.047
31.
UdaondoPHernandezCBrianso-LlortL, et al.Usefulness of liquid biopsy biomarkers from aqueous humor in predicting anti-VEGF response in diabetic macular edema: results of a pilot study. J Clin Med2019; 8. DOI: https://doi.org/10.3390/jcm8111841
32.
PaineSKBhattacharjeeCKBhaduriG, et al.Pre-therapeutic biomarkers for ranibizumab therapy among type 2 diabetic patients with diabetic macular edema. Optom Vis Sci2021; 98: 81–87. DOI: https://doi.org/10.1097/OPX.0000000000001622
33.
CohenL. Relationships between visual function and metabolism. In: CohenLHNoellWK (eds) Biochemistry of the Eye. Orlando, FL: Academic Press, 1965, pp.36–50.
34.
BonninSManeVCouturierA, et al.New insight into the macular deep vascular Plexus imaged by optical coherence tomography angiography. Retina2015; 35: 2347–2352. DOI: https://doi.org/10.1097/IAE.0000000000000839
AshrafMSoukaAAdelmanR. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. Br J Ophthalmol2016; 100: 1596–1604. DOI: https://doi.org/10.1136/bjophthalmol-2016-308388
37.
BakerCWGlassmanARBeaulieuWT, et al.Effect of initial management with aflibercept vs Laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the Macula and good visual acuity: a randomized clinical trial. Jama2019; 321: 1880–1894. DOI: https://doi.org/10.1001/jama.2019.5790
38.
WykoffCC. Thresholds for initiating treatment of eyes with diabetic macular edema and good vision: consideration of DRCR.net protocol V results. Ophthalmol Retina2019; 3: 917–919. DOI: https://doi.org/10.1016/j.oret.2019.07.007
39.
WellsJAGlassmanARJampolLM, et al.Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. JAMA Ophthalmol2016; 134: 127–134. DOI: https://doi.org/10.1001/jamaophthalmol.2015.4599
40.
YoshitakeTMurakamiTSuzumaK, et al.Predictor of early remission of diabetic macular edema under as-needed intravitreal ranibizumab. Sci Rep2019; 9: 7599. DOI: https://doi.org/10.1038/s41598-019-44078-6
41.
ZurDIglickiMBuschC, et al.OCT Biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. Ophthalmology2018; 125: 267–275. DOI: https://doi.org/10.1016/j.ophtha.2017.08.031
42.
VujosevicSTorresinTBiniS, et al.Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema. Acta Ophthalmol2017; 95: 464–471. DOI: https://doi.org/10.1111/aos.13294
43.
EatonAKohSSJimenezJ, et al.The USER study: a chart review of patients receiving a 0.2 µg/day fluocinolone acetonide implant for diabetic macular edema. Ophthalmol Ther2019; 8: 51–62. DOI: https://doi.org/10.1007/s40123-018-0155-5
44.
SivaprasadSCrosby-NwaobiRHengLZ, et al.Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT report 5). Br J Ophthalmol2013; 97: 1177–1180. DOI: https://doi.org/10.1136/bjophthalmol-2013-303168
45.
BaileyCChakravarthyULoteryA, et al.Real-world experience with 0.2μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye (Lond)2017; 31: 1707–1715. DOI: https://doi.org/10.1038/eye.2017.125
46.
PessoaBDiasDABaptistaP, et al.Vitrectomy outcomes in eyes with tractional diabetic macular edema. Ophthalmic Res2019; 61: 94–99. DOI: https://doi.org/10.1159/000489459
47.
AntoszykANGlassmanARBeaulieuWT, et al.Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: a randomized clinical trial. Jama2020; 324: 2383–2395. DOI: https://doi.org/10.1001/jama.2020.23027
